David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab (Avastin) plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
There is still not enough data to say there is synergy between these 2 agents, but so far there has been an increase in progression-free survival (PFS) and response rates compared to standard cytotoxic chemotherapies.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More